ABEO stock forecast, quote, news & analysis
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company... Show more
Why Abeona Therapeutics (ABEO) Stock Is Down -52% in the Last 30 Days
Key Takeaways
- Abeona Therapeutics (ABEO) shares have declined roughly 52% over the last 30 days, falling from about $4.90 to near $2.36.
- The sharpest leg down came after third-quarter results and the acquisition of ABO-801, which triggered a single-session drop of more than 35%.
- Third-quarter ZEVASKYN revenue of $13.5 million rose 18% sequentially but came in below consensus, renewing concerns about launch execution.
- A $30 million private placement and a stock-based acquisition increased dilution and weighed on investor sentiment.
- Manufacturing variability and a planned annual manufacturing shutdown have added near-term uncertainty around revenue timing.
- The stock has also weakened substantially over the past quarter, retreating from about $7.40 in early August.
- For additional detail on valuation and catalysts, review Abeona Therapeutics' Price Targets, Earnings, and Forecast pages.
- Explore Trending AI Robots to see how algorithmic strategies are positioning across the market.
Abeona Therapeutics (ABEO) Company Overview and Market Position
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on cell and gene therapies for rare and serious diseases. Its lead marketed product, ZEVASKYN (prademagene zamikeracel), is an autologous cell-based gene therapy approved to treat wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB), a rare and severe skin condition. The company recently added ABO-801, a Phase 3-ready, once-daily oral fluticasone propionate tablet for eosinophilic esophagitis (EoE), and continues to advance ABO-701, an investigational engineered T-cell therapy targeting PSMA. Abeona also holds licensing arrangements with partners including Ultragenyx Pharmaceutical and Taysha Gene Therapies that carry potential milestone and royalty payments. Investors follow the stock primarily for the commercial ramp of ZEVASKYN, pipeline diversification, and the company's path toward profitability.
Abeona Therapeutics (ABEO) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, ABEO has declined approximately 52%, moving from a closing level near $4.90 to roughly $2.36. The decline was not gradual: most of the damage occurred in a single session in early November, when the shares fell more than 35% and broke below the prior 52-week low. The move extended a longer slide, with the stock retreating from about $7.40 in early August to current levels, a decline of roughly 68% over the past quarter. The trend reflects repeated disappointments around the commercial launch and a broader shift in sentiment toward execution risk.
What Drove ABEO Stock Price in the Last 30 Days
The dominant catalyst was the company's third-quarter earnings release and a simultaneous strategic announcement. Abeona reported net ZEVASKYN revenue of $13.5 million, up 18% sequentially from $11.4 million, but below analyst expectations. Management also disclosed that one treatment batch could not be billed because it was out of specification on an identity assay, underscoring the complexity of commercial-scale gene therapy manufacturing.
At the same time, the company announced the acquisition of APT-1011 (renamed ABO-801) from Ellodi Pharmaceuticals for $20 million in stock with no upfront cash, plus milestone and royalty obligations. The deal was paired with a $30 million private placement of common shares and pre-funded warrants. The combination of a revenue miss, manufacturing variability, and incremental equity dilution drove the sharp sell-off, as investors reassessed near-term cash burn and the trajectory of the ZEVASKYN launch.
What Drove ABEO Stock Performance Over the Last Quarter
The quarterly decline reflects a cumulative loss of confidence that began with second-quarter results in August. In that report, ZEVASKYN revenue of $11.4 million grew 31% sequentially but missed expectations, and the shares fell more than 10%. A subsequent analyst price-target reduction added to the pressure. Over the following months, the stock drifted lower as the market weighed manufacturing yield issues, patient scheduling variability, and the pace of treatment adoption. The early-November earnings miss and the dilutive acquisition and financing extended this trend, reinforcing a narrative of slower-than-modeled commercialization and rising execution risk.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots from a much larger universe of hundreds of automated strategies trading thousands of tickers. Only the top-performing and most relevant bots appear in this section, giving traders a focused view of strategies currently attracting attention. The featured bots vary widely in approach, holding timeframe, and performance metrics, so the page serves as a discovery tool rather than a single recommendation. For investors looking to complement their own research with systematic, data-driven signals, reviewing the Trending AI Robots section can offer additional context on how algorithmic models are navigating current market conditions.
ABEO Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, investors are likely to focus on the pace of ZEVASKYN treatment volume and revenue recognition, particularly as the company works through a planned annual manufacturing shutdown that pauses biopsy collection into early next year. Manufacturing consistency and the ability to bill each batch remain central execution risks. The planned Phase 3 program for ABO-801 in eosinophilic esophagitis, including discussions with the FDA and an anticipated mid-2027 start, will also shape sentiment given the program's development costs and timeline. Reimbursement developments such as the New Technology Add-On Payment pathway and any milestone or royalty income from partners represent potential positive offsets. Broader macroeconomic conditions, biotech sector sentiment, and the company's cash runway will continue to influence the stock, though none of these factors constitute investment advice or a guarantee of future performance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ABEO in -41.13% downward trend, declining for three consecutive days on November 10, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ABEO declined for three days, in 270 of 320 cases, the price declined further within the following month. The odds of a continued downward trend are 84%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ABEO as a result. In 75 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
The Moving Average Convergence Divergence Histogram (MACD) for ABEO turned negative on November 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 37 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
The 50-day moving average for ABEO moved below the 200-day moving average on October 21, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
The Aroon Indicator for ABEO entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +2.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABEO advanced for three days, in 209 of 253 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
ABEO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.862) is normal, around the industry mean (3.498). P/E Ratio (-3.446) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (13.089) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. ABEO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABEO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of pharmaceutical products
Industry Biotechnology